Provectus Biopharmaceuticals Announces Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Treatment of Checkpoint-Refractory Advanced Cutaneous Melanoma at Society for Melanoma Research (SMR) 2021
October 28, 2021 06:00 ET
|
Provectus Biopharmaceuticals Inc.
34.1 months median overall survival, 4.9 months median progression-free survivalBest overall response (RECIST 1.1): 5% CR, 26% ORR, 53% DCR (19 patients) KNOXVILLE, TN, Oct. 28, 2021 (GLOBE...
Provectus Biopharmaceuticals Provides Update on Research into Oral Administration of PV-10® Immunotherapy for Treatments of Hematology, Oncology, and Virology
October 04, 2021 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on the Company’s research into the systemic administration of Provectus’ investigational...
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2021 Congress
September 27, 2021 06:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from historical clinical trials and expanded access studies of investigational cancer...
Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at European Society for Medical Oncology (ESMO) Congress 2021
September 21, 2021 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract at European Society for Medical Oncology (ESMO) Congress 2021
July 19, 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, July 19, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal disodium)...
Provectus Biopharmaceuticals Announces Publication of In Vitro Data from Research on Oral Delivery of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
June 09, 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines tested — Represents prerequisite in vitro data for clinical testing...
Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
June 04, 2021 09:00 ET
|
Provectus Biopharmaceuticals Inc.
— Systemic disease control achieved in heavily pre-treated liver cancer patients — 83% DCR; median PFS of 9.2 months; median OS of 22.5 months; half of patients undergoing response...
State of Tennessee Awards Funding for Public-Private Partnership to Study Animal Cancers and Dermatological Disorders using Provectus’ Medical Science Platform
May 25, 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 25, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the State of Tennessee, as part of its fiscal year 2021-2022 budget, has directed funding in the amount...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
April 28, 2021 12:35 ET
|
Provectus Biopharmaceuticals Inc.
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) — Systemic administration of PV-10 for treatment of solid tumor...
Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions
March 31, 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
46% complete response of patients at Melanoma Institute AustraliaFifth published study of in-transit melanoma lesion treatment with single-agent PV-1026-50% complete response (52-86% overall response)...